A Phase 2 interventional study of Naproxen gel and Diclofenac gel in Soft Tissue Injury, sponsored by Bayer. Completed at 1 site in Germany. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-01-22.
Sponsored by Bayer · Phase 2, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Researchers are looking for a different way to treat people who have an injury to their muscles, ligaments, or tendons in their legs or feet. This is known as a "soft tissue" injury. Before a treatment is available to all patients, researchers study it in trials to better understand its safety and how well it works.
People with soft tissue injuries can have pain, swelling, and bruising.
In this trial, the researchers want to learn more about the trial treatment, BAYH006689, in participants with a soft tissue injury to their legs or feet. BAYH006689 is a naproxen gel that is used for the temporary relief of minor aches and pains of muscles and joints. The researchers will learn more about how BAYH006689 works and how safe it is in these participants.
The trial will include about 100 male and female participants between the ages of 18 and 60. All the participants will have a soft tissue injury to their legs or feet that was caused by playing sports. The injury will have happened within 3 hours of joining the trial.
The researchers will use a computer program to randomly choose what treatment each participant will receive. This will help make sure the treatments are chosen fairly and that comparing the results of the treatments is as accurate as possible. The participants will be randomly chosen to be in 1 of 3 groups:
A placebo looks like a treatment but does not have any medicine in it. Diclofenac diethylamine gel is a treatment already available for doctors to be recommended to people with soft tissue injuries. The participants will receive their treatment once in the evening on Day 1 and then 2 times a day for 4 days. The participants will receive their final dose in the morning of Day 6. The doctors will apply the treatment to the participants' skin where the injury is.
The participants must be present at the clinic site 11 times over six days: once on Day 1 and twice daily on Days 2-6. During the trial, the doctors will:
In this trial, the researchers will study how tender the participants' injuries are after 3 days and at other time points over the 6 day follow-up period. They will also study how many participants have medical problems during the trial.
64 studies on the registry are indexed under Soft Tissue Injuries; 7 are open to participants now.
This study's enrollment of 76 is above the median of 60 across 51 interventional studies indexed under Soft Tissue Injuries.
Browse Soft Tissue Injuries studies →Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 133 (62%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other Exclusions
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
UI Number: 1614000-268; Subjects will be randomized into one of the three treatment groups in a 2:2:1 (active:active:placebo) allocation. Treatment consists of a twice daily (bid) application (approximately 12 hours apart) of the assigned topical gel over 5 consecutive days, beginning on the evening of Day 1 and ending (last application) on the morning of Day 6 (total of 10 applications). In order to assure adequate representation of different types of soft tissue injuries, at least 25 randomized subjects must enter the study with a lower extremity sprain/strain injury (cohort) and at least 50 randomized subjects with a lower extremity contusion injury (cohort).
Drug: Naproxen gel
UI Number: Not applicable; Subjects will be randomized into one of the three treatment groups in a 2:2:1 (active:active:placebo) allocation. Treatment consists of a twice daily (bid) application (approximately 12 hours apart) of the assigned topical gel over 5 consecutive days, beginning on the evening of Day 1 and ending (last application) on the morning of Day 6 (total of 10 applications). In order to assure adequate representation of different types of soft tissue injuries, at least 25 randomized subjects must enter the study with a lower extremity sprain/strain injury (cohort) and at least 50 randomized subjects with a lower extremity contusion injury (cohort).
Drug: Diclofenac gel
UI Number: 1614000-272; Subjects will be randomized into one of the three treatment groups in a 2:2:1 (active:active:placebo) allocation. Treatment consists of a twice daily (bid) application (approximately 12 hours apart) of the assigned topical gel over 5 consecutive days, beginning on the evening of Day 1 and ending (last application) on the morning of Day 6 (total of 10 applications). In order to assure adequate representation of different types of soft tissue injuries, at least 25 randomized subjects must enter the study with a lower extremity sprain/strain injury (cohort) and at least 50 randomized subjects with a lower extremity contusion injury (cohort).
Drug: Placebo gel
10%, bid for 5 days (final application on morning of Day 6)
2.32% bid for 5 days (final application on morning of Day 6)
bid for 5 days (final application on morning of Day 6)
Tenderness (Algometry) Over the Initial 72 Hours
Algometry area under the curve (AUC) from zero to the initial 72h post dose. The 72h AUC algometry data was an aggregate of all measurements from timepoints and data including the 72h timepoint. The average data of all participants was reported.
Time frame: Up to the initial 72 hours post dose
Percentage of Participants With at Least One Treatment Emergent Adverse Event After Treatment
An AE is any untoward medical occurrence in a clinical study participant, associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: After first treatment on Day 1 until follow-up visit (Day 30)
Number of Participants With at Least One Treatment Emergent Adverse Event After Treatment
An AE is any untoward medical occurrence in a clinical study participant, associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: After first treatment on Day 1 until follow-up visit (Day 30)
The study was conducted in three centers in Germany. First participant first visit of the study was on 08 AUG 2021, and last participant last visit was on 20 DEC 2021.
| Milestone | Naproxen Topical Gel | Diclofenac Diethylamine Topical Gel | Placebo |
|---|---|---|---|
| Started | 31 | 30 | 15 |
| Completed | 31 | 30 | 15 |
| Not completed | 0 | 0 | 0 |
Algometry area under the curve (AUC) from zero to the initial 72h post dose. The 72h AUC algometry data was an aggregate of all measurements from timepoints and data including the 72h timepoint. The average data of all participants was reported.
| Nxh/cm^2 | Naproxen Topical Gel | Diclofenac Diethylamine Topical Gel | Placebo |
|---|---|---|---|
| Tenderness (Algometry) Over the Initial 72 Hours | 1213.88 ± 461.11 | 1041.04 ± 274.25 | 850.79 ± 276.04 |
An AE is any untoward medical occurrence in a clinical study participant, associated with the use of study intervention, whether or not considered related to the study intervention.
| Percentage | Naproxen Topical Gel | Diclofenac Diethylamine Topical Gel | Placebo |
|---|---|---|---|
| any AE | 0 | 3.33 | 0 |
| serious AE | 0 | 0 | 0 |
An AE is any untoward medical occurrence in a clinical study participant, associated with the use of study intervention, whether or not considered related to the study intervention.
| Participants | Naproxen Topical Gel | Diclofenac Diethylamine Topical Gel | Placebo |
|---|---|---|---|
| Rhinitis | 0 | 1 | 0 |
| Nasal congestion | 0 | 1 | 0 |
| Paranasal sinus hypersecretion | 0 | 1 | 0 |
Collected over Adverse event data were collected after first treatment on Day 1 until follow-up visit (Day 30).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Naproxen Gel | 0/31 (0%) | 0/31 (0%) | 0/31 (0%) |
| Diclofenac Gel | 0/30 (0%) | 0/30 (0%) | 1/30 (3.3%) |
| Placebo Gel | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) |
| Event | Naproxen Gel | Diclofenac Gel | Placebo Gel |
|---|---|---|---|
| RhinitisInfections and infestations | 0/31 | 1/30 | 0/15 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 0/31 | 1/30 | 0/15 |
| Paranasal sinus hypersecretRespiratory, thoracic and mediastinal disorders | 0/31 | 1/30 | 0/15 |
| Age, Continuous(years) | Naproxen Topical Gel | Diclofenac Diethylamine Topical Gel | Placebo | Total |
|---|---|---|---|---|
| Mean | 33.32 ± 10.74 | 31.57 ± 9.47 | 32.47 ± 13.05 | 32.46 ± 10.64 |
| Sex: Female, Male(Participants) | Naproxen Topical Gel | Diclofenac Diethylamine Topical Gel | Placebo | Total |
|---|---|---|---|---|
| Female | 16 | 16 | 9 | 41 |
| Male | 15 | 14 | 6 | 35 |
| Race (NIH/OMB)(Participants) | Naproxen Topical Gel | Diclofenac Diethylamine Topical Gel | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 0 | 1 |
| White | 29 | 30 | 15 | 74 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Naproxen Topical Gel | Diclofenac Diethylamine Topical Gel | Placebo | Total |
|---|---|---|---|---|
| Non-Hispanic/Latino | 21 | 19 | 10 | 50 |
| Other | 9 | 11 | 5 | 25 |
| Unknown | 1 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — There are no current plans to share data. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
Ran from Aug 2021 to primary completion in Dec 2021, 4 months.
Results were first posted in Jan 2025, 3 years 1 month after primary completion. A results delay was requested in Dec 2022.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Naproxen